Immuneering's Phase 2a Trial Yields 17.3-Month Median Overall Survival for Pancreatic Cancer Patients
Market Chameleon (Fri, 22-May 10:30 AM)
Immuneering’s Atebimetinib Combo Delivers 17.3-Month Median Overall Survival in First-Line Metastatic Pancreatic Cancer—What Sets This Result Apart?
Market Chameleon (Fri, 22-May 7:29 AM)
